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Background: Retroviruses encode a very limited number of proteins and therefore must exploit a wide variety of
host proteins for completion of their lifecycle.
Methods: We performed an insertional mutagenesis screen to identify novel cellular regulators of retroviral replication.
Results: This approach identified the ATP-dependent chromatin remodeler, chromodomain helicase DNA-binding
protein 2 (CHD2), as well as the highly related CHD1 protein, as positive regulators of both MLV and HIV-1 replication in
rodent and human cells. RNAi knockdown of either CHD2 or the related CHD1 protein, in human cells resulted in a
block to infection by HIV-1, specifically at the level of transcription.
Conclusions: These results demonstrate that CHD1 and CHD2 can act as positive regulators of HIV-1 gene expression.
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Retroviruses cause a wide range of diseases in humans
and animals, including cancer (HTLV-1, and HTLV-2)
and AIDS (HIV-1 and HIV-2) in humans. These viruses
exploit a large number of cellular proteins and other
factors to facilitate different steps of virus replication.
The early stages of retrovirus replication involve virus-
receptor and -co-receptor interactions, membrane fusion,
cytosolic entry, reverse transcription, nuclear import and
integration of the viral genome into a host chromosome
to form the provirus. The late stages involve proviral
transcription, viral RNA splicing, polyadenylation and
cytoplasmic transport, protein translation, and viral
assembly, budding and maturation.
A number of comprehensive genetic screens, most
relying on RNAi-knockdown technology, have revealed a
number of cellular factors that are important for replica-
tion by retroviruses such as HIV-1 [1-4]. While this is a
powerful approach, its impact is limited by the fact that
the RNAi-knockdown level seen with individual genes
is often incomplete, i.e. expression of the target gene is
reduced but is not completely ablated. To overcome* Correspondence: jyoung@salk.edu
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unless otherwise stated.this potential limitation of this technology, we are
adopting complementary approaches including insertional
mutagenesis-based screening. This approach has revealed
important regulators of retroviral replication that were
missed by siRNA screening, including ZASC1, a key
regulator of HIV-1 transcriptional elongation [5,6] and
the cellular sulfonation pathway that also regulates
retroviral gene expression [7].
Here we describe results of another insertional muta-
genesis screen that have revealed CHD2, and the related
CHD1 protein, as positive regulators of HIV-1 gene ex-
pression. These proteins are members of the chromodo-
main helicase DNA binding protein (CHD) family of
ATP-dependent chromatin remodelers, which are import-
ant regulators of chromatin structure and transcription
[8]. Currently there are four distinct families of ATP-
dependent chromatin remodelers, including the SWI/SNF,
ISWI, INO80 and CHD families, and all are characterized
by the presence of a SWI2/SNF2-family ATPase domain
[9]. These chromatin remodelers utilize the energy of ATP
hydrolysis to move, eject or restructure nucleosomes,
thereby controlling the access of regulatory proteins to
DNA or histones [10]. The CHD family of proteins is
distinguished by the presence of two tandem chromodo-
mains located in the N-terminal region of the protein in
addition to the centrally located SWI2/SNF2-familyl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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gle CHD1 protein, mammals express nine different CHD
proteins [11].
Currently, CHD1 is the better characterized of these two
proteins. CHD1 localizes to regions of active transcription
and interacts with transcription elongation complexes in-
cluding the PAF and FACT complexes [12-15]. The yeast
CHD1 protein can exist as a monomer or a dimer [16,17],
and is an essential component of the yeast SAGA and
SLIK HATcomplexes [16]. The chromodomains of human
CHD1 can specifically bind methylated H3K4 suggesting a
possible mechanism for targeting the protein to sites of
active transcription [9,18]. More recent biochemical stud-
ies have implicated the chromodomains as having a role in
enzymatic activity and not localization [19]. Genome-wide
localization studies in mouse ES cells demonstrated that
CHD1 binding correlates with RNA polymerase II (Pol II)
and the activating H34Kme3 mark, although bivalent
domains enriched in both the H3K4me3 mark and the
repressive H3K27me3 mark lack CHD1 [20]. In vitro stud-
ies have found that human CHD1 can be targeted to active
genes through its interaction with the mediator complex
[21]. CHD1 has also been shown to be required for the
maintenance of open chromatin and pluripotency of mur-
ine embryonic stem cells [20]. In addition, high resolution
ChIP-seq experiments revealed that CHD1 is recruited to
the promoters of actively transcribed genes, where it evicts
the nucleosomes downstream of the promoter allowing
for PolII promoter escape [5]. Although CHD1 localizes to
regions of active transcription and is generally associated
with transcriptional activation, previous studies have indi-
cated that CHD1 plays a negative role in regulating HIV-1
basal transcription and maintaining latency [22,23].
CHD2 is a member of the CHD1 subfamily, which is
characterized by an additional DNA-binding domain lo-
cated in the C-terminal region [8]. Studies in CHD2 mutant
mice suggest possible roles for this protein in development,
DNA damage signaling, and maintenance of genome stabil-
ity [24,25]. In addition, both CHD1 and CHD2 can regulate
deposition of the histone variant H3.3 [26,27]. Here we
show that CHD1 and CHD2 can both regulate HIV-1 gene
expression.
Results
Isolation of MLV-resistant clones using magnetic cell
sorting (MACS)
An insertional mutagenesis screening approach was used
to identify novel host factors, which regulate the early
stages of retroviral replication. This technique, called
SILENCE, uses long terminal repeat (LTR)-encoded cis-
acting response elements to induce transcriptional re-
pression in CHO-K1 cells [28]. This system employs a
mutagenic MLV vector, CMMP. GFP-NEO-TRE and the
trans-acting repressor protein tetR-KRAB (TKR), whichin the absence of doxycycline, binds to (7 tandem TetO
sequences; TRE) located in the long terminal repeat
(LTR) region of the mutagenic vector, inducing revers-
ible heterochromatin formation and transcriptional re-
pression within 3 kb of flanking cellular DNA [29,30].
Since MLV DNA is preferentially integrated close to cel-
lular gene transcription start sites [31], this approach
can result in conditional silencing of cellular gene
expression.
The SILENCE cells used in this study have been previ-
ously described [28]. Ten separate pools of SILENCE
cells were cultured for 72 h in the absence of doxycyc-
line in order to repress transcription of host genes near
the integrated provirus containing the TREs (Figure 1A).
5 × 106 cells per pool were challenged with replication-
defective, VSV-G pseudotyped MLV encoding the hu-
man CD4 gene (CMMP-CD4 [VSV-G]), at an MOI of
approximately 1.0 for 2 h at 37°C. 28 hpi, infected cells,
which express CD4 on their surface, were depleted from
the population by magnetic cell sorting (MACS) using
an iron-conjugated CD4 antibody. After selection, unin-
fected cells were allowed to recover in media containing
doxycycline, thus allowing for transcription of any si-
lenced genes. After five rounds of selection, one pool of
cells (designated as 6/B) was resistant to MLV infection
as compared to wild-type CHO-K1 cells (data not shown).
This resistant cell population, which exhibited 2.0-fold re-
duced levels of infectivity compared to wild type CHO-K1
cells, was single cell cloned by limiting dilution and the
resulting clones were tested for their susceptibility to
infection by a VSV-G pseudotyped MLV vector which
encodes luciferase (VGIP-Luc [VSV-G]) (data not shown).
Prior to viral challenge, cells were cultured for 72 h in
either the presence or absence of doxycycline to deter-
mine whether MLV resistance was doxycycline-mediated.
At 28 hpi, luciferase activity was measured. Two MLV-
resistant cell lines, 6/B-6 and 6/B-7 were identified,
although MLV resistance in these clones was not
doxycycline-mediated, indicating that disruption of the
cellular gene by the mutagenic vector is not dependent
on the tetR-KRAB repressor protein. These two cell lines
were further characterized and are described below.
The mutant CHO-K1 cell lines display resistance to infection
by both MLV and HIV-1
To determine if the defect in the 6/B-6 and 6/B-7 mu-
tant cell lines was specific to MLV or if it affects HIV-1
infection, wild type CHO-K1 cells and mutant cell lines
were seeded in 96 well plates and challenged with either
a VSV-G pseudotyped MLV reporter virus VGIP-Luc
[VSV-G] or a VSV-G pseudotyped HIV-1 reporter virus
pNL43-Luc-R+E− [VSV-G] encoding luciferase. At 24 hpi
luciferase activity was measured. A luminescent cell viabil-
ity assay was utilized to monitor viable cell number and to
Figure 1 Isolation and characterization of retrovirus-resistant clones. (A) Strategy used to isolate MLV-resistant clones. Transcriptional repression
of cellular genes flanking the mutagenic vector was induced in ten independent pools of SILENCE cells by withdrawal of doxycycline for 72 h. The cells
were then challenged with a VSV-G pseudotyped MLV vector, CMMP-CD4 [VSV-G], encoding human CD4, at a MOI of approximately 1.0 CD4-transducing
units. Infected cells were depleted from the population by magnetic separation using an iron-conjugated CD4 antibody. Uninfected cells were allowed to
recover in medium containing doxycycline for a minimum of 72 h, prior to a subsequent round of infection and selection. After five rounds of infection
and selection, the 6B pool was considered to be relatively resistant to MLV infection, based on the resultant numbers of CD4-expressing cells. Individual
cell clones were derived from this pool by limiting dilution and virus resistance was verified by challenging with a VSV-G pseudotyped MLV
vector, VGIP3-Luc [VSV-G] encoding firefly luciferase. (B) Resistance of two mutant cell clones to infection by MLV and HIV-1 vectors. Wild type CHO-K1
and the 6/B-6 and 6/B-7 mutant CHO-K1 cell clones were challenged with VSV-G pseudotyped vectors encoding firefly luciferase: VGIP3-Luc or NL43 R
+ E- Luc. Cell viability was also monitored using the CTG assay. The ratios of firefly luciferase activity: cell viability were determined and compared to
that of wild type CHO-K1 cells (defined as 100% infection). The data shown is the average mean of three independent experiments each performed
with triplicate samples. Error bars indicate the standard deviation. The data was analyzed using an unpaired T-test, ***P value <0.0001.
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ing plating and different growth rates. Cells lines 6/B-6 and
6/B-7 exhibited a 67% and 65% reduction in MLV reporter
gene expression as compared to that seen with wild type
CHO-K1 cells (Figure 1B). Viral reporter gene expression
following infection with VSV-G pseudotyped HIV-1 re-
porter virus was reduced to similar levels seen with theVSV-G pseudotyped MLV vectors in both 6/B-6 and 6/B-7
(Figure 1B), indicating that the affected genes in the mutant
cell lines are important for both MLV and HIV-1 infection.
The mutant cell lines did display a modest growth defect
compared to the wild type CHO-K1 cells (Figure 1B),
although this defect may be caused by the presence of mul-
tiple antibiotics in the media and not the defective gene.
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(CHD2) gene is disrupted in the mutant CHO-K1 cell clones
Southern blot analysis revealed that the 6B-6 and 6B-7
cell clones each contained a single mutagenic CMMP.
GFP-NEO-TRE provirus (data not shown). We then
employed Inverse PCR to determine the integration site
of the mutagenic CMMP. GFP-NEO-TRE virus in the
6/B-6 and 6/B-7 cell lines as described in the materials
and methods section. This analysis revealed that the mu-
tagenic viral vector was integrated near the 5’-end of
intron 2 of the Chromodomain-helicase-DNA-binding
protein 2 (CHD2) gene in both cell lines (Figure 2A),
therefore the two cell clones were derived from the same
virus-resistant cell in the 6B cell population. Consistent
with gene disruption, CHD2 mRNA levels were decreased
by approximately 50% in cell clones 6B-6 and 6B-7 relative
to wild-type CHO-K1 cells (Figure 2B). These data suggest
that disruption of the CHD2 gene may confer resistance
to retroviral infection in CHO-K1 cells.
CHD2 and the related CHD1 protein positively regulate
retrovirus infection in human cells
To determine if CHD2 also positively regulates retroviral
infection in human cells, both loss-of-function and gain-
of-function experiments were performed in HEK293T
cells. This cell line was chosen for this study because of
its high efficiency of RNAi-knockdown and cDNA over-
expression. We also included the highly related CHD1
protein in this analysis since CHD2 is a member of the
CHD1 subfamily of CHD proteins [11].
RNAi-knockdown of CHD1 and CHD2 protein levels
was achieved with 2 independent siRNAs targeting each
gene (Figure 3A) and without any overt cell toxicity
(Figure 3B and 3C). The siRNA transfected cells were
challenged with the VSV-G pseudotyped VGIP-Luc MLV
vector, or the pNL43-Luc-R+E− HIV-1 vector, and virus-
encoded luciferase activity was measured. Depletion of
either CHD1 or CHD2 had a significant impact on MLVFigure 2 The mutagenic viral vector is integrated into the CHD2 gene
integrated into intron 2 of the hamster CHD2 gene. The DNA sequence aro
boundary and the adjacent viral DNA (bold and underlined). (B) Quantitati
β-actin mRNA levels in wild type and mutant cells. The ratios of CHD2 mRNA
cells (defined as 100% Control). The data shown is the average mean of three
The data was analyzed using an unpaired T-test, ***P value <0.0001.and HIV reporter gene expression as compared to a nega-
tive control siRNA (Figure 3B and 3C). We also reprodu-
cibly noted that RNAi-knockdown of CHD1 led to a
modest increase in the level of CHD2 protein (Figure 3A),
an effect that was also seen at the mRNA level (data not
shown).
The siRNAs targeting both CHD-1 and CHD-2 also
led to a modest but highly reproducible and statistically
significant decrease in HIV-1 reporter gene expression
in human SupT1 cells, a T-cell line that is more physio-
logically relevant for HIV-1 infection (Figure 3D, right
panel). Reduced infection in this case was associated
with a decrease in CHD1 mRNA levels, as CHD2 mRNA
was not depleted in these experiments (Figure 3D, left
panel).
In the gain-of-function studies, epitope tagged versions
of CHD1 or CHD2 (V5-tagged CHD1 or Myc/His-tagged
CHD2) were expressed in HEK293T cells (Figure 3E).
These cells were challenged with the VSV-G pseudotyped
pNL43-Luc-R+E− HIV-1 reporter virus and infection was
measured by virus-encoded firefly luciferase as before.
The efficiency of HIV-1 reporter gene expression was
significantly enhanced in cells that overexpressed either
epitope tagged-CHD1 or -CHD2, compared to the empty
plasmid vector controls (Figure 3F). Cell viability was not
affected under these conditions. Taken together, these
results demonstrate that CHD1 and CHD2 are positive
regulators of HIV-1 gene expression in human cells.
The effect of CHD1 and CHD2 in HEK293T cells maps to
HIV-1 transcription
Real-time quantitative PCR analysis revealed that RNAi-
knockdown of either CHD1 or CHD2 in HEK293T cells
did not impact the levels of reverse transcribed HIV-1
DNA (data not shown) or HIV-1 proviral DNA (Figure 4A).
However, real-time quantitative PCR analysis revealed a
significant reduction in all HIV-1 mRNA transcripts in
cells transfected with either CHD1 or CHD2 siRNAsin the mutant cell clones. (A) The TRE mutagenic viral vector is
und the integration site is expanded to show the exon2/intron2
ve RT-PCR was used to measure CHD2 mRNA levels relative to control
: β-actin mRNA were determined and compared to wild type CHO-K1
independent experiments. Error bars indicate the standard deviation.
Figure 3 CHD2 and CHD1 regulate retroviral infection in human cells. (A) siRNAs targeting CHD1 and CHD2 were transfected into HEK293T cells. A
non-targeting siRNA (Neg) and a siRNA targeting the virus-encoded luciferase (GL3) were used as controls. (Left panel) Immunoblot analysis of CHD1,
CHD2 and tubulin protein levels at 48 hours post-transfection. (Right panel) Protein levels were quantified using the Licor Odyssey infrared imaging system
and the ratios of CHD1 or CHD2 protein:tubulin were determined and compared to the non-targeting control (defined as 100% Control). The data shown
is the average mean of three independent experiments. (B) HEK293T cells transfected with the siRNAs were challenged with the MLV vector or (C) the
HIV-1 vector. The ratios of luciferase activity:cell viability were determined and compared to the non-targeting control (defined as 100% infection).
(D) siRNAs targeting both CHD1 and CHD2, or a control siRNA (Neg) were transfected into SupT1 cells. (Right panel) The cells were challenged
with the HIV-1 vector as described above. (Left panel) CHD1 and CHD2 mRNA levels were measured by qRT-PCR. The ratios of CHD1 or CHD2
mRNA:GAPDH mRNA were determined and compared to the non-targeting control (defined as 100% Control). (Right panel) The ratio of virus-encoded
luciferase activity:viable cell number was determined and compared to the non-targeting control (defined as 100% infection). (E) Immunoblot analysis
of CHD1-V5, CHD2-Myc/His and tubulin protein levels at 48 hours post-transfection in transfected HEK293T cells. (F) The cDNA-expressing cells were
challenged with the HIV-1 vector at 48 hours post-transfection. The ratio of virus-encoded luciferase activity:viable cell number was determined and
compared to the non-targeting control (defined as 100% infection). The data shown is the average mean of three independent experiments each
performed with triplicate samples. Error bars indicate the standard deviation. The data was analyzed using an unpaired T-test, ***P value <0.0001.
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Figure 4 CHD1 and CHD2 positively regulate HIV-1 transcription. (A) siRNAs targeting CHD1 and CHD2, or a control siRNA (Neg) were
reverse transfected into HEK293T cells. 48 hours post-transfection the cells were challenged with the VSV-G pseudotyped HIV-1 viral vector NL43
R + E- Luc and incubated for 7 days to eliminate extrachromosomal HIV-1 DNA. qPCR analysis was performed to measure the level of integrated
viral DNA. The ratio of viral DNA: PBGD control was determined and compared to the non-targeting control (defined as 100% control). (B) Schematic
of the HIV-1 reporter virus and the location of the oligonucleotide primers used for qRT-PCR amplification of viral RNA transcripts. The short primer set
amplifies the first 59 nucleotides of the HIV transcript and will amplify both the short abortive transcripts and the full-length transcripts. The luciferase
primers will amplify only elongated viral transcripts. (C) Measurement of short and long HIV-1 transcripts at 24 hpi in cells transfected with siRNAs
targeting CHD1 or CHD2 and challenged with the VSV-G pseudotyped HIV viral vector NL43 R + E- Luc. The HIV-1 RNA levels were measured by
qRT-PCR and the ratios of HIV RNA: β-actin mRNA were determined and compared to the non-targeting control siRNA (defined as 100% Control).
(D) HEK293T cells were transfected with plasmids encoding epitope-tagged CHD1 or CHD2 proteins and challenged with the VSV-G pseudotyped HIV
viral vector NL43 R + E- Luc. The HIV-1 RNA levels were measured by qRT-PCR as above using the ERT primers. The ratios of HIV RNA: β-actin mRNA
were determined and compared to the empty vector controls (defined as 100% Control). The data shown is the average mean of three independent
experiments. Error bars indicate the standard deviation. The data was analyzed using an unpaired T-test, *P value <0.01, ***P value <0.0001.
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Although we did not observe the characteristic increase in
the short abortive transcripts associated with a defect in
elongation, these results do not preclude the possibility of
a role in elongation or other downstream steps in the tran-
scription cycle. Consistently, we detected an increase in the
levels of HIV-1 mRNA transcripts in cells transfected with
the epitope-tagged CHD1 or CHD2 proteins (Figure 4D).
Taken together, these data are consistent with a role
for CHD1 and CHD2 as positive regulators of HIV-1
transcription.
Discussion
In this report we provide genetic evidence that the chro-
modomain proteins CHD1 and CHD2 are positive regu-
lators of retroviral replication. Firstly, an insertional
mutagenesis screen identified CHD2 as the disrupted
gene in mutant CHO-K1 cells that were resistant toMLV and HIV-1 infection. Secondly, gain-of-function and
loss-of-function experiments in HEK293T cells confirmed
that CHD2 and the highly related CHD1 protein positively
regulate MLV and HIV-1 infection. Thirdly, siRNAs tar-
geting CHD1 reduced HIV-1 infection of human SupT1 T
cells. The effect of these two chromodomain proteins was
mapped to a stage in transcription, which precedes elong-
ation, indicating that CHD1 and CHD2 play a role early in
the transcription cycle. The effect of these proteins on
virus replication is consistent with their known roles in
the cell. Different members of the CHD family generally
function at different steps during cellular gene transcrip-
tion and can act as either transcriptional activators or
repressors [32]. CHD1 localizes to H3K4me3 positive pro-
moters [20] and to regions of active transcription [15],
and is associated with transcriptional activation.
In contrast to our findings, studies that used a chimeric
yeast-HIV transcription model, implicated CHD1 as a
Rodgers et al. Virology Journal 2014, 11:180 Page 7 of 11
http://www.virologyj.com/content/11/1/180repressor of HIV-1 basal transcription [22]. The difference
between these findings and our result could be due to
the choice of experimental model systems. While the
yeast CHD1 protein’s main role during transcription is
reassembly and repositioning of nucleosomes in the
gene body during elongation, the mammalian CHD1
also functions at the promoter where it promotes nucleo-
some destabilization in order to overcome the nucleosome
barrier to Pol II promoter escape [5,6,33]. In addition, un-
like the mammalian protein, the yeast CHD1 chromodo-
mains lack the key residues required for binding to
methylated H3K4 [9,18], which is predicted to influence
both localization and activity [19]. CHD1 has also been
linked to the maintenance of HIV latency via transcrip-
tional interference in two J-Lat clones E27 and A2, which
harbor a HIV minigenome within introns of highly active
cellular genes [23]. In the transcriptional interference
model of virus latency it has been proposed that CHD1
and other chromatin assembly factors associated with
transcriptional elongation can exert their repressive effects
by assembling chromatin into a closed repressive config-
uration thereby silencing the HIV promoter [23]. CHD1
does have what appears to be opposing activities at dif-
ferent steps during the transcription cycle, which could
account for the different results seen in our study. Early
in the transcription cycle, CHD1 promotes nucleosome
destabilization at promoters, resulting in efficient Pol II
promoter escape and downstream progression; while dur-
ing elongation, CHD1 promotes nucleosome stabilization
and inhibits cryptic transcription [5,6]. While the relation-
ship of these findings, obtained with proviruses that are
also subject to negative regulation by a highly active cellu-
lar gene, and our results with cells newly infected with
MLV or HIV-1 is not yet clear, it is important to note that
our findings are consistent with the established role of
the CHD1 subfamily of proteins as activators of gene
transcription.
Possible models of CHD1 and CHD2 regulation of
retroviral gene expression include histone modification
and/or nucleosome remodeling events. In addition, CHD1
and CHD2 may affect other factors needed for HIV tran-
scription either by recruiting factors to the HIV LTR or by
acting at the promoters of the required host gene. It is
also possible that these cellular proteins might influence
HIV-1 DNA integration site specificity, which in turn
could influence the efficiency of viral transcription. Fu-
ture experiments will be aimed at determining precisely
how these two proteins regulate HIV-1 gene expression.
Conclusions
In this study, we employed an insertional mutagenesis
screening technique in CHO-K1 to identify novel cellular
regulators of retroviral infection. This technique initially
identified the ATP-dependent chromatin remodeler, CHD2,as a positive regulator of both MLV and HIV-1 replica-
tion. Gain-of-function and loss-of-function experiments
performed in human cells confirmed that CHD2 and the
highly related CHD1 protein positively regulate MLV and
HIV-1 infection. The requirement for CHD1 or CHD2
was more specifically mapped to an early stage of viral
transcription, which is consistent with their known roles
in the cell. These results demonstrate that both CHD1
and CHD2 are important positive regulators of HIV-1
gene expression. Future studies will provide a more de-
tailed view of the role of CHD1 and CHD2 in the tran-
scription cycle of HIV-1 infection and will further
contribute to our understanding of epigenetic regulation
of transcription during HIV infection.
Materials and methods
Ethics statement
No animals or human subjects were used in this study.
Plasmids
The viral genome plasmids pCMMP-CD4, pVGIP3 and
pNL43-Luc-R+E− have been described previously [7,34,35].
The CHD1 Gateway entry clone (HsCD00365806) was
acquired from Dana-Farber/ Harvard Cancer Center DNA
Resource Core. The CHD1-V5 expression clone was gen-
erated by transferring the CHD1 cDNA from the entry
clone to the Gateway pcDNA6.2/V5-DEST (Invitrogen)
destination vector by LR recombination. The CHD2
cDNA was synthesized from total RNA isolated from
293 T cells using the SuperScript III First Strand Syn-
thesis Kit (Invitrogen) and the gene specific primer
CHD2(CD)-R1 (Table 1). The CHD2-Myc/His expression
clone was generated by PCR amplification of the coding
sequence from CHD2 cDNA using the primers CHD2-
XhoI-F3 and CHD2-BamHI-R6 (Table 1). PCR products
were digested with XhoI and BamHI and cloned into
pCDNA3.1-Myc/His (Invitrogen).
Cell culture and virus production
Chinese hamster ovary CHO-K1 cells were cultured in
F-12 media (Invitrogen) supplemented with 10% FBS
(Hyclone). Human embryonic kidney 293 T cells were
cultured in DMEM (Invitrogen) supplemented with 10%
FBS (Hyclone). The human CD4+ T-cell line SupT1 was
cultured in RPMI (Invitrogen) supplemented with 10%
FBS (Hyclone). SILENCE cells [28] were provided by Dr.
Kenneth A. Bradley and were cultured as described above
for CHO-K1 cells with the addition of 900 μg/mL G418
(Gibco), 10 μg/mL puromycin (Gibco), and 1 μg/mL
doxycycline (Sigma).
VSV-G pseudotyped MLV virus was generated by
cotransfection of 293 T cells with the appropriate viral
genome plasmid, pMD.gagpol encoding MLV Gag/Pol
[33] and pCMV-VSV-G encoding the VSV envelope
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natant was harvested, filtered, and stored at −80°C, as
described previously [2]. VSV-G pseudotyped HIV-1 lucif-
erase reporter virus was generated by cotransfection of
293 T cells with pNL43-Luc-R+E− and pCMV-VSV-G
[36]. 48 h post-transfection, retroviral supernatant was
harvested, filtered, and treated with DNaseI (Roche) to re-
move contaminating plasmid DNA. The virus was then
aliquoted and stored at −80°C, as described previously [2].
Isolation of MLV-resistant CHO-K1 cells
Ten separate pools, each consisting of 5 × 106 SILENCE
cells [28] were cultured for 72 h in the absence of doxy-
cycline, followed by infection with CMMP-CD4 [VSV-G]at an approximate MOI 1.0 CD4 transducing units for 2 h
at 37°C in the presence of 4 μg/ml Polybrene. After 2 h,
virus-containing media was removed and replaced with
fresh media. At 28 h post-infection (hpi), cells were
detached from plates with 5 mM EDTA/Dulbecco's
phosphate-buffered saline (DPBS) and washed with cold
DPBS. Cells were resuspended in PBE (DPBS supple-
mented with 1% BSA and 2 mM EDTA) and incubated
with human CD4 microbeads (Miltenyi Biotec Inc.) for
15 min at 4°C. Large cell (LC) columns (Miltenyi Biotec
Inc.) were placed in the OctoMACS magnetic separator
(Miltenyi Biotec Inc.) and washed with 1 ml of PBE. Cell
suspensions were filtered through a 30 μm MACS pre-
separation filters (Miltenyi Biotec Inc.) before being ap-
plied to the pre-washed LC columns. Cells were washed
three times with 0.5 ml of PBE. The flow through and
washes were collected and the cells were pelleted and
plated in medium containing doxycycline. Cells were ex-
panded and allowed to recover for a minimum of 72 h be-
fore the next viral challenge. The infection and selections
were repeated as before for a total of five times at which
time there was observable resistance to MLV infection in
mutant cell pool 6/B compared to wild type CHO-K1
cells. The resistant 6/B pool was then subjected to single
cell cloning by limiting dilution in 96-well plates. In order
to identify MLV-resistant clones, single cell clones from
pool 6/B were plated in replicate 96-well plates and one
plate was challenged with VGIP3-Luc [VSV-G] in the
presence of 4 μg/ml Polybrene. At 28 hpi, luciferase
activity was quantitated with the BrightGlo luciferase
assay (Promega) and the second plate was assayed for
viable cell number using the CellTiter-Glo cell viability
assay (Promega).
Quantitative MLV and HIV Infectivity assays (CHO-K1 cells)
For each cell line tested, 1 × 104 cells were seeded in 9
wells of a black 96 well plate. The following day cells
were infected with either VGIP3-Luc [VSV-G] or NL43-
Luc-R+E− [VSV-G] in the presence of 4 μg/ml Polybrene
in triplicate wells. 24 hpi, luciferase activity was quanti-
tated with the BrightGlo luciferase assay (Promega) and
the uninfected wells were assayed for viable cell number
using the CellTiter-Glo cell viability assay (Promega).
Luciferase results were normalized to cell number.
Nested inverse PCR
Genomic DNA (gDNA) was isolated using the PURElink
genomic DNA mini kit (Invitrogen, Carlsbad, CA.). 2 μg
of gDNA was digested overnight with PstI in a total vol-
ume of 40 μl. The following day the restriction enzyme
was heat-inactivated for 20 min at 65°C and 20 μl of the
sample was used in a ligation reaction with T4-ligase
(NEB) in a final volume of 1 ml and incubated overnight
at room temperature. The DNA was phenol/chloroform
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round of PCR was performed using 2 μl of ligated-DNA
as template with MLV-specific primers iPCR1 and iPCR2
(Table 1). The second nested round of PCR was per-
formed with 2 μl of the first PCR reaction with the
primers iPCR3 and iPCR4 (Table 1). The PCR products
were then cloned into the pCR®-Blunt II-TOPO® Vector
(Invitrogen) and sequenced.RNAi experiments
The small interfering RNAs (siRNAs) used in these experi-
ments were human CHD1 1–6 (On-TARGETplus CHD1
si-6, Dharmacon), CHD1 1–8 (On-TARGETplus CHD1
si-8, Dharmacon), CHD2 2–6 (On-TARGETplus CHD2 si-
6, Dharmacon), CHD2 2–8 (On-TARGETplus CHD2 si-8,
Dharmacon) ON-TARGETplus Non-targeting siRNA #1
(Dharmacon) and Luciferase GL3 (Qiagen). siRNAs were
reverse transfected into HEK293T cells in either 96 (x 3
replicates) or 48 well plates using the Lipofectamine
RNAiMAX transfection reagent (Invitrogen). siRNAs and
Lipofectamine RNAiMAX were diluted separately into
Optimem (Invitrogen), diluted siRNAs were then added
to wells followed by the addition diluted Lipofectamine
RNAiMAX. After 20 min, aliquots of HEK293T cells
freshly resuspended in DMEM supplemented with 20%
FBS (Invitrogen) were added to each well. For chemilu-
minescent infectivity assay, cells were infected 48 h
post-transfection with either VGIP3-Luc [VSV-G] or
NL43-Luc-R+E− [VSV-G] in triplicate wells of a 96 well
plate. 24 hpi, luciferase activity was quantitated with the
BrightGlo luciferase assay (Promega) and the uninfected
wells were assayed for viable cell number using the
CellTiter-Glo cell viability assay (Promega). Luciferase
results were normalized to cell number.
siRNAs were transfected into SupT1 cells using the
Neon Transfection System (Invitrogen) according to the
manufacturer’s protocol. Briefly cells were resuspended
at a concentration of 2 × 107 cells/ml in 10 μl Buffer R
and mixed with siRNAs. Cells were electroporated using
protocol number #24 (1600 (V), 10 (pulse width), 3
(pulse #) and then transferred to the well of a 24-well
plate containing 400 μl of complete RPMI media. 48 h
post-transfection 600 μl of fresh complete RPMI media
was added to each well and 100 μl of cells were ali-
quoted into two 96-well plates (x 3 replicates). Cells
were then infected with NL43-Luc-R+E− [VSV-G] or
mock-infected with media in triplicate wells and spinocu-
lated for 90 min at 1200 × g at 25°C. At 24 hpi, luciferase
activity was quantitated with the BrightGlo luciferase
assay (Promega) and the mock-infected wells were assayed
for viable cell number using the CellTiter-Glo cell viability
assay (Promega). Viral reporter luciferase results were
normalized to cell number.Viral DNA and RNA quantitation by real-time qPCR
To measure proviral DNA content in infected cells,
HEK293T cells were reverse transfected in 48 well plates
with siRNAs as described above. 48 h post-transfection
cells were infected with DNAase I treated NL43-Luc-R
+E− [VSV-G]. 24 hpi, the virus containing media was re-
moved and the cells were dislodged from each well and
transferred to 6 well plates. At 7 days post-infection
(dpi) genomic DNA was isolated using the PURElink gen-
omic DNA mini kit (Invitrogen, Carlsbad, CA.). qPCR re-
actions were performed using 30 ng of genomic DNA
and the primer-probe sets; MH531, MH532V, probe
LRT-P [2,37] for quantitating viral DNA, and PBGD1,
PBGD2 and probe PBGD-P [2] for the cellular gene por-
phobilinogen deaminase (PBGD) (Table 1). Real-time PCR
assays were performed in triplicate using TaqMan Fast
Universal PCR Master Mix (Applied Biosystems). The
number of copies in each reaction was quantified using a
standard curve produced by amplification of plasmid
DNA containing the appropriate target sequence. Pro-
viral DNA levels were normalized to PBGD copy
number.
To measure HIV RNA transcript levels in infected
HEK293T cells were reverse transfected in 48 well plates
with siRNAs as described above. 48 h post-transfection
cells were infected with DNAase I treated NL43-Luc-R
+E− [VSV-G]. 24 hpi total RNA was isolated using the
miRNeasy Mini Kit (Qiagen). cDNA synthesis was per-
formed using the QuantiTech Reverse Transcription Kit
(Qiagen). The following primer sets were used for Real-
time qPCR: for short HIV transcripts; HIV Start and
HIV Short 3’ [38]; for HIV full-length transcripts; Lucif1
and Lucif2; for Beta-actin; ACTB-F and ACTB-R. Real-
time PCR assays were performed in triplicate using Fast
Sybr Green Master Mix (Applied Biosystems). The num-
ber of copies in each reaction was quantified using a
standard curve produced by amplification of plasmid
DNA containing the appropriate target sequence. HIV
RNA transcripts were normalized to ACTB copy number.
Immunoblotting
The antibodies used for immunoblot analysis were
CHD1 (Bethyl Laboratories), CHD2 (Cell Signaling), α/
β-Tubulin (Cell Signaling) and Alexa Fluor 680 donkey
anti-rabbit IgG (Invitrogen). 48 h post-transfection cells
were lysed in 2x NuPAGE LDS sample buffer (Invitro-
gen) and resolved by SDS-PAGE on NuPAGE 4-12%
Bis-Tris gels (Invitrogen). Proteins were transferred to
Immobilon-FL PVDF membranes (Millipore) and mem-
branes were for blocked for 1 h in 0.1% Casein/0.2x PBS
(Biorad). The membrane was then probed with primary
antibody in blocking buffer +0.1% Tween-20 overnight at
4°C. Membranes were washed three times with PBS +0.1%
Tween-20, then incubated with Alexa Fluor 680 donkey
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Tween-20 + 0.01% SDS for 1 h at room temperature. Im-
munoblots were washed, then visualized and quantitated
using an Odyssey infrared imaging system (Licor). CHD1
and CHD2 protein levels were normalized to α/β-Tubulin
levels.mRNA quantitation by real-time quantitative PCR
Total RNA was isolated using the RNeasy Mini kit
(Qiagen). cDNA synthesis was performed using the
QuantiTech Reverse Transcription Kit (Qiagen). For
RNAi experiments, total RNA was isolated 48 h post-
transfection. The following primer sets were used for
Real-time qPCR: for CHD2 in CHO-K1 cells; CgCHD2-F3
and CgCHD2-R3; for β-Actin in CHO-K1 cells; CgACTB-
F1 and CgACTB-R1; for CHD1 in human cells; CHD1-F
and CHD1-R; for CHD2 in human cells; CHD2-F3 and
CHD2-R3; for β-Actin in 293 T cells; ACTB-F and ACTB-
R; for GAPDH in SupT1 cells; GAPDH-F2 and GAPDH-
R2 (Table 1).Transient transfection assays
Plasmid DNA was transfected into HEK293T cells in ei-
ther 96 or 48 well plates using the Transit LT-1 transfec-
tion reagent (Mirus). For chemiluminescent infectivity
assays, cells were infected 48 h post-transfection NL43-
Luc-R+E− [VSV-G] in triplicate wells of a 96 well plate. At
24 hpi, luciferase activity was quantitated with the Bright-
Glo luciferase assay (Promega) and the uninfected wells
were assayed for viable cell number using the CellTiter-
Glo cell viability assay (Promega,). Luciferase results were
normalized to cell number. To measure HIV RNA tran-
script levels, HEK293T cells were transfected with plasmid
DNA in 48 well plates. 48 h post-transfection cells were
infected with DNAase I treated NL43-Luc-R+E− [VSV-G].
At 24 hpi total RNA was collected and analyzed as de-
scribed previously for siRNA experiments, using the pri-
mer sets; ERT2F and ERT2R for viral RNA transcripts
[39] and ACTB-F and ACTB-R for Beta-actin (Table 1).
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